SubHero Banner

Truseltiq (infigratinib) – New drug approval

May 28, 2021 - BridgeBio Pharma, through its affiliate QED Therapeutics, and Helsinn Group announced the FDA approval of Truseltiq (infigratinib), for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test.

Download PDF